AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

More Potent and Metabolically Stable HIV/AIDS Therapeutics

Summary

Researchers at Purdue University have developed a series of alkenyldiarylmethane (ADAM) NNRTIs that inhibit the cytopathic effect of HIV-1 in CEM-SS cells and MT-4 cells and offer potential value in the treatment of AIDS. These ADAMs were developed through research on an original 25 ADAMs tested with different methyl ester bioisosteres at three different locations. This research resulted in inhibitors proven to be more potent and designed to be more metabolically stable than the original lead compound. This new series of compounds also includes an inhibitor effective against the resistant K103N mutant reverse transcriptase.

Technology Benefits

More potent inhibitor Metabolically stable K103N mutant inhibitor

Technology Application

AIDS/HIV treatment Research & Development

Detailed Technology Description

Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology

Countries

United States

Application No.

None

Country/Region

USA

For more information, please click Here